GlassScriptPhysician profile
David Allen Breitweiser
NPI 1194715854
$3,493.49
in general payments reported to CMS, 2019-2025
25 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $64.69 · 2021: $34.57 · 2022: $411 · 2023: $806 · 2024: $778 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $787.36 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $447.03 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $432.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $305.22 | 2024-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $219.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $153.27 | 2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $139.09 | 2022-2025 | |
| Abbvie INC. | $133.74 | 2022-2025 | Vraylar |
| Exact Sciences Corporation | $111.45 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $97.77 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $86.17 | 2022-2025 | |
| Mylan Specialty L.P. | $83.86 | 2022-2024 | Yupelri |
| Abbott Laboratories | $78.67 | 2022-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.13 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $46.52 | 2022-2023 | Veozah, Myrbetriq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.94 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $45.13 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.29 | 2022 | |
| Merck Sharp & Dohme LLC | $40.97 | 2019-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Axsome Therapeutics, INC. | $27.24 | 2025 | Auvelity |
| Biogen, INC. | $26.57 | 2025 | Zurzuvae |
| Corium, LLC | $19.17 | 2025 | Azstarys |
| Dexcom, INC. | $18.39 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $17.30 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Breitweiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.